Sangamo Therapeutics, Inc. SGMOQ

SGMOQ Company Overview

Sangamo Therapeutics, Inc. is a publicly traded biotechnology company focused on developing genomic medicines that aim to treat serious genetic and neurological diseases. The company operates within the biotechnology and gene therapy industries, with core capabilities spanning genome editing, gene regulation, and gene replacement therapies. Its programs are designed to address conditions with high unmet medical need, including rare monogenic diseases and central nervous system disorders.

Founded in 1995, Sangamo was an early pioneer of zinc finger protein (ZFP) technology, one of the first programmable DNA-binding platforms used for targeted genome modification. Over time, the company expanded its approach to include AAV-based gene therapy and ZFP transcription factor (ZFP-TF) platforms for epigenetic regulation. While several early programs were discontinued following clinical or strategic reassessments, Sangamo has evolved into a more focused clinical-stage organization centered on select late-stage and mid-stage assets, particularly in Fabry disease and neurological disorders.